Zai Lab (ZLAB) expects continued rigorous financial discipline and: Total revenue to be in the range of $560 million to $590 million for full-year 2025; On a non-GAAP basis, achieve profitability in the fourth quarter of 2025
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab’s Strategic Advancements and Global Potential in SCLC Treatment with ZL-1310
- Zai Lab announces China’s NMPA accepted NDA for KarXT
- Zai Lab announces results from innovaTV 301 study
- Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
- Zai Lab enters Tmalin license agreement with MediLink Therapeutics